Carisma Therapeutics Stock Surges 165% on Merger Update with Ocugen
Carisma Therapeutics (CARM) shares skyrocketed 165% in pre-market trading following updates on its merger with Ocugen's subsidiary OrthoCellix. The biopharmaceutical firm secured commitments for up to $30 million in combined funding, including a $25 million share purchase agreement and a $5 million subscription deal from Ocugen.
CEO Steven Kelly will retain leadership post-merger, with equity incentives tied to the deal's completion. The stock's dramatic rebound comes after a 48.8% YTD decline, fueled by heavy trading volume as investors reposition around the restructuring.